1. Pfizer's stock price has halved since 2022 due to patent expirations. 2. The company reported better-than-expected earnings but missed revenue forecasts. 3. Pfizer's stock now yields 7.4%, attractive compared to junk bonds. 4. Dividend payments are secure, reaffirmed despite tariff uncertainties. 5. CFRA analyst rates Pfizer as a 'buy' supported by diverse drug portfolio.
Despite recent challenges, the substantial dividend yield offers potential upside for investors. Historical examples show that stable dividends can support stock prices during downturns.
The article highlights both ongoing challenges and attractive elements, making it relevant for current and potential investors of PFE.
Pfizer's ongoing commitment to dividends and portfolio diversification will gradually build investor confidence, especially as Covid-related earnings stabilize. Investors typically take a longer view when balanced with consistent dividends.